Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02322827

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART — HOST  

Acquired Immunodeficiency Syndrome Clinical Trial

Official title:
Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed a Single Tablet Regimen (STR) Versus Multi Tablet Regimen (MTR).

Clinical Trial Summary

This study is designed to see how HIV infected patients perform when taking a single fixed dose HIV medication compared to a regimen with multiple tablets. The study is also going to be looking at the differences in complications between the two groups.

Clinical Trial Description

This is a phase IV retrospective chart review of HIV infected patients in a private Infectious disease practice in West Palm Beach, FL. This chart review will assign patients into one of two groups based on their antiretroviral regimen: single tablet regimen (STR) versus multi tablet regimen (MTR). Up to 650 patient charts will be reviewed but only about 500 patients are needed for statistical analysis.

The primary objective is to look at the proportion of patients with an adherence rate greater than or equal to 95% in subjects prescribed STR versus a MTR.

Secondary Objectives:

- Differences in emergency room visits, hospitalization and readmission in patients taking a STR vs. a MTR

- Proportion of patients with HIV viral load less than 50copies/microliter

- Incidence of new onset or worsening hyperlipidemia in patients taking a STR versus a MTR

- Incidence of acute renal insufficiency

- Compare the absolute CD4 number increase between a STR and a MTR

- Compare monthly copay amounts in patients taking a STR versus a MTR

- Identify the incidence of opportunistic infections in patients taking a STR versus a MTR ;

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02322827
Study type Observational
Source Triple O Research Institute PA
Contact
Status Completed
Phase N/A
Start date November 2014
Completion date October 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Completed NCT02929069 - A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk N/A
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT02583464 - Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. Phase 1
Completed NCT02264509 - Peripheral Arterial Insufficiency Associated With HIV/AIDS N/A
Completed NCT01440569 - Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Phase 3
Completed NCT00551330 - Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED) Phase 2
Completed NCT00381212 - A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. Phase 1/Phase 2
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00001409 - Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications Phase 1
Completed NCT00000590 - Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Phase 3
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Completed NCT00005273 - Pulmonary Complications of HIV Infection Study (PACS) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00001650 - Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients N/A
Withdrawn NCT00243568 - Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 Phase 3
Recruiting NCT05031819 - Managing Hypertension Among People Living With HIV N/A
Completed NCT00394004 - Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials N/A
Completed NCT01967940 - Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults Phase 3